New drug combo targets Hard-to-Treat tumors in early trial

NCT ID NCT06640413

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-stage study is testing a new drug, [177Lu]Lu-OncoFAP-23, alone or with another drug (L19-IL2), in people with advanced solid tumors that have a protein called FAP. The main goal is to see if the treatment is safe and to find the best dose. About 56 adults whose cancer has not responded to standard treatments will take part.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for FAP are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

classic familial adenomatous polyposis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • ASST Papa Giovanni XXIII Piazza OMS

    RECRUITING

    Bergamo, Bergamo, 24127, Italy

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

  • Fondazione IRCCS Istituto Nazionale dei Tumori

    RECRUITING

    Milan, Milano, 20133, Italy

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

  • Istituto Europeo di Oncologia

    NOT_YET_RECRUITING

    Milan, Milano, 20141, Italy

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

  • Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale" Via Mariano Semmola

    NOT_YET_RECRUITING

    Naples, Napoli, 80131, Italy

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact